Basit öğe kaydını göster

Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer

dc.contributor.authorKarabulut, Senem
dc.contributor.authorSerilmez, Murat
dc.contributor.authorDuranyildiz, Derya
dc.contributor.authorTas, Faruk
dc.contributor.authorKARABULUT, Mehmet
dc.date.accessioned2021-03-04T18:32:06Z
dc.date.available2021-03-04T18:32:06Z
dc.date.issued2016
dc.identifier.citationTas F., Karabulut S., Serilmez M., KARABULUT M., Duranyildiz D., "Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer", CANCER CHEMOTHERAPY AND PHARMACOLOGY, cilt.77, ss.127-131, 2016
dc.identifier.issn0344-5704
dc.identifier.othervv_1032021
dc.identifier.otherav_8b3b38a3-3a98-4f0d-919c-6f9c419eb60d
dc.identifier.urihttp://hdl.handle.net/20.500.12627/94282
dc.identifier.urihttps://doi.org/10.1007/s00280-015-2886-5
dc.description.abstractMonocyte chemoattractant protein 1 (MCP-1/CCL-2) is a member of the CC chemokine family and a potent chemotactic factor for monocytes that regulate migration and infiltration of monocytes and macrophages. It plays an important role in the pathogenesis of multiple malignancies, and its expression strongly also affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of MCP-1/CCL-2 in gastric cancer patients.
dc.language.isoeng
dc.subjectPharmacology, Toxicology and Pharmaceutics (miscellaneous)
dc.subjectPharmacology (medical)
dc.subjectOncology
dc.subjectPharmacy
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectDrug Guides
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectPharmacology
dc.subjectGeneral Pharmacology, Toxicology and Pharmaceutics
dc.titleElevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer
dc.typeMakale
dc.relation.journalCANCER CHEMOTHERAPY AND PHARMACOLOGY
dc.contributor.departmentBakirkoy Dr. Sadi Konuk Research & Training Hospital , ,
dc.identifier.volume77
dc.identifier.issue1
dc.identifier.startpage127
dc.identifier.endpage131
dc.contributor.firstauthorID33441


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster